#COSM – Cosmos Health Orderbook Surges Past 32.7 Million Units Cosmos Health ($COSM) is continuing to expand its contract manufacturing business, with its Cana Laboratories subsidiary adding another major long-term agreement. 📦 New 5-Year Agreement Cana has signed new five-year manufacturing agreements with Target Pharma covering approximately: • 1.04 million units annually • 5.2 million units over five years • Expansion into cardiovascular and anti-infective therapeutic categories With this addition, Cana’s cumulative contract manufacturing orderbook has now climbed above 32.7 million units. That is a significant increase from the 25+ million units reported in June, representing roughly 31% growth in the orderbook since then. 📈 Why This Matters The bigger story for $COSM is not just the number of units. The company is building a growing base of multi-year manufacturing contracts. These agreements can provide better visibility into future production volumes and potential recurring cash flows. Cana is also becoming more diversified across therapeutic areas. The latest Target Pharma agreements add cardiovascular and anti-infective products to the company's manufacturing portfolio. 🏭 Cana Laboratories Cana operates Cosmos Health’s 54,000-square-foot pharmaceutical manufacturing facility in Athens, Greece. The facility is EU-GMP licensed and EMA certified, and Cosmos Health has invested about $5.5 million in modernization, equipment, IT infrastructure and quality systems. The growing orderbook could therefore help the company improve utilization of this manufacturing infrastructure. 🔥 Recent Momentum The Target Pharma deal follows another five-year agreement announced just days earlier with Viofar. That agreement added approximately 2.5 million units of ROSARTIA, a cardiovascular medicine, taking the orderbook above 27.5 million units at that time. So in a very short period, COSM has added several million units of contracted production. 💡 Investor Takeaway The interesting part of the $COSM story is shifting from simply growing healthcare brands to building a larger recurring contract-manufacturing business. A 32.7M+ unit orderbook gives Cana significantly more production visibility, but investors still need to watch how quickly these contracts convert into actual revenue, margins and cash flow. #COSM #CosmosHealth #Pharma #Healthcare #ContractManufacturing #Biotech #SmallCaps #Stocks